Standard Versus High Dose ED-Initiated Buprenorphine Induction
Status:
RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This study is a multisite double-blind, double-dummy, randomized clinical trial enrolling ED patients with untreated moderate to severe opioid use disorder (OUD) to compare Standard Dose Induction (SDI) and High Dose Induction (HDI) on rates of participation in OUD treatment within 10 days post randomization, and opioid withdrawal symptoms, opioid craving, and use of illicit and non-prescribed drugs.
Phase:
PHASE3
Details
Lead Sponsor:
Yale University
Collaborators:
Alameda Health System National Drug Abuse Treatment Clinical Trials Network National Institute on Drug Abuse (NIDA) The Emmes Company, LLC
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination